NASDAQ · Biotechnology · USD

Kailera Therapeutics, Inc. (KLRA) Stock Analysis

Kailera Therapeutics, Inc. (KLRA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KLRA

$16.23

+$0.49 (+3.11%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KLRA with… →

KLRA Key Statistics

As of Sep 4, 2026

Trading

Open: $15.60
Previous Close: $15.74
Day's Range: 15.57–16.44
52-Week Range: 15.15–28.23
Volume: 523.30K

Valuation

Market Cap: $2.10B
P/E Ratio: unprofitable
EPS (ttm): −2.25

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$148.96M
Profit margin: 0.00%
Shares Outstanding: 129.64M

Dividend and dates

Earnings Date: October 29, 2026estimated
Avg Volume: 778.78K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KLRA Valuation vs Biotechnology Median

Median of 656 stocks

Metric	KLRA	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Kailera Therapeutics, Inc. (KLRA) is capitalised at $2.10B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 145.

The most recent close on file for KLRA is $16.23, dated September 4, 2026. That is +$0.49 (+3.11%) against the previous close. The 52-week range on file runs from $15.15 to $28.23. The latest close sits 7.13% above that 52-week low.

Financial Health

In fiscal 2025, Kailera Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $148.96M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −2.25.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Growth & Income

The record shows no dividend for KLRA.

So far in 2026 the price is −37.58%.

Peer Comparison

Kailera Therapeutics, Inc. (KLRA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Kailera Therapeutics, Inc.	KLRA	$2.10B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Kailera Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Visit website →